Black Hawk Secures $200M Equity Line and Backstop Financing with Meteora
BKHA sits 21% above its 52-week low of $10.09 on light trading volume (0.2× avg).
Summary
Black Hawk and Vesicor entered financing agreements with Meteora on Sept 22, including a forward purchase agreement covering up to 1,350,000 shares and a $200 million equity line over 36 months. The company will pay Meteora the final redemption price less $0.75 per backstop investor share. This financing package supports the pending Vesicor merger, which faces an October 13 shareholder vote and a required $10M PPM financing condition. The backstop and equity line reduce near-term liquidity risk and strengthen the merger's closing prospects. Watch for the shareholder vote outcome and completion of the PPM financing.
Updates
· SEC 425 — The 425 details a $200M standby equity purchase agreement with 97% pricing, a forward purchase for up to 1,350,000 shares at $10 reset, a non-redemption backstop for up to 2,124,077 shares, and a subscription agreement.
At the time of this announcement, BKHA was trading at $12.19 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $50.6M. The 52-week trading range was $10.09 to $13.10. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Reuters.